University of British Columbia-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2019

  1. PIK3CA alterations and benefit with neratinib: Analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

    Breast Cancer Research, Vol. 21, Núm. 1

2015

  1. Defining breast cancer intrinsic subtypes by quantitative receptor expression

    Oncologist, Vol. 20, Núm. 5, pp. 474-482

2013

  1. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 203-209

  2. Reply to Y. Yamamoto et al

    Journal of Clinical Oncology

2012

  1. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers

    BMC Medical Genomics, Vol. 5

2009

  1. Reply to L.C. Panasci

    Journal of Clinical Oncology

  2. Reply to R.S. Mehta et al

    Journal of Clinical Oncology